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Abstract
Purpose The aim of this study was to examine risk factors for
nodal recurrence in the lateral neck (NRLN) in patients with
papillary thyroid cancer (PTC) who underwent total thyroidec-
tomy with prophylactic central neck dissection (TT + pCND).
Methods This was a retrospective cohort study of patients with
PTC who underwent TT + pCND. Data of all patients treated
over a 10-year period (between 1998 and 2007) were analysed.
The primary outcome was prevalence of NRLN within the
5-year follow-up after initial surgery. Predictors of NRLN were
determined in the univariable and multivariable analysis.
Results Of 760 patients with PTC included in this study, 44
(6.0 %) developed NRLN. In the univariable analysis, the
following factors were identified to be associated with an
increased risk of NRLN: positive/negative lymph node
ratio ≥0.3 (odds ratio (OR) 14.50, 95 % confidence interval
(CI) 7.21 to 29.13; p <0.001), central lymph node metastases
(OR 7.47, 95 % CI 3.63 to 15.38; p <0.001), number of level
VI lymph nodes <6 in the specimen (OR 2.88, 95%CI 1.21 to
6.83; p =0.016), extension through the thyroid capsule
(OR 2.55, 95 % CI 1.21 to 5.37; p =0.013), localization of
the tumour within the upper third of the thyroid lobe (OR 2.35,
95 % CI 1.27 to 4.34; p =0.006) and multifocal lesions
(OR 1.85, 95 % CI 1.01 to 3.41; p =0.048).
Conclusions Central lymph node metastases together with
positive to negative lymph node ratio ≥0.3 represent the
strongest independent prognostic factors for the PTC recur-
rence in the lateral neck.
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Introduction
Papillary thyroid cancer (PTC) is the most common endocrine
malignancy and accounts for the majority of cases of thyroid
cancer in iodine-sufficient areas of the world [1]. Most PTCs
that are diagnosed are small and are generally regarded as
being low risk, with little or no effect on mortality. It is widely
accepted that total thyroidectomy (TT) is the procedure of
choice for all PTCs above 10 mm in size [2, 3]. Lymph node
metastases are a common finding in PTC, occurring in
20–50 % of patients in the central compartment of the neck
(level VI) and in 10–30 % in the lateral compartment of the
neck (levels II –V) [4]. A strong expert consensus supported
by evidence emerging from large studies is that when lymph
nodes are palpable or visible on ultrasonography, en bloc
compartment-oriented lymph node dissection should be per-
formed, as opposed to the so-called berry picking of only the
obviously abnormal nodes because the former approach is
associated with a lower risk of recurrence and mortality de-
spite earlier reports of no adverse effects on survival [1, 5, 6].
When there is no suspicion of metastatic disease to lymph
nodes on imaging or palpation, prophylactic or elective central
neck dissection (pCND) is a matter of debate [7–18].
Proponents of routine pCND argue that removing subclinical
lymph node involvement reduces disease persistence. On the
other hand, opponents of routine pCND underline the absence
of evidence for improvement of long-term outcomes with
resection of occult microscopic nodal metastases.
Nevertheless, several respected organizations have recently
recommended that TT plus pCND should be the standard
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operation for PTC [2, 3]. However, it has been clearly shown
that 55 % of patients with metastatic level VI nodes identified
after pCND also had metastatic nodes within levels III and IV,
which would remain unrecognized without prophylactic lat-
eral neck dissection (pLND) [19]. Thus, pCND together with
pLND has a potential to provide optimized staging of cN0
PTC patients. Nevertheless, while pCND remains controver-
sial, prophylactic LND is regarded as even more controversial
and is rarely attempted.
The aim of this retrospective cohort study of patients un-
dergoing surgery at our tertiary referral unit was to identify
risk factors for nodal recurrence in the lateral neck in patients
with PTC who underwent TT with pCND.
Methods
Study design and patient selection
This is a retrospective cohort study of 760 patients with PTC
and clinically negative lymph nodes who were treated at the
Third Department of General Surgery, Jagiellonian University
Medical College in Krakow, Poland, between 1998 and 2007
and who were identified from the institutional computer-based
register of thyroid surgery. The study group comprised pa-
tients who underwent TT with bilateral pCND and had a
complete postoperative five-year follow-up. All the patients
provided written informed consent for the storage and use of
their data.
The inclusion criterion was a pathological diagnosis of
PTC in a patient with lacking clinical evidence of nodal
disease (cN0 status based on negative physical exam, neg-
ative preoperative neck ultrasound and no lymphadenopa-
thy evident at surgery). The exclusion criteria were poorly
differentiated thyroid carcinoma, incidental diagnosis of
PTC, one-stage lymph node dissection based on therapeutic
intent, distant metastasis at diagnosis, previous thyroid
surgery, incomplete clinical data, follow-up information
or histopathology report and ASA grade 4 (American
Society of Anaesthesiology).
The following definition of clinically apparent lymph
nodes necessitating therapeutic CND was used: palpable
lymph nodes on physical examination, positive preoperative
neck ultrasound and/or lymphadenopathy evident at surgery.
The ultrasound criteria of lymph node malignancy recognized
in this study as the exclusion criteria were the size of 1.0 cm or
larger, cystic appearance, hyperechoic punctuations, absence
of a hilum and peripheral vascularization. All the ultrasound
examinations were performed by experienced radiologists
trained in neck ultrasound.
The primary outcome measure was prevalence of nodal
recurrence in the lateral neck within the 5-year follow-up after
initial surgery. The secondary outcome measures were the
prevalence of postoperative hypoparathyroidism and recurrent
laryngeal nerve (RLN) injury. This project was approved by
the institutional review board.
Surgical technique
Operations in both groups were performed by experienced
endocrine surgeons, who followed a standardized technique of
thyroidectomy described below. In both groups, the operation
consisted of total extracapsular thyroidectomy with bilateral
prophylactic level VI lymph node clearance (according to the
American Thyroid Association classification) [2, 4]. The
prelaryngeal lymph nodes, sitting directly anteriorly to the
cricothyroid membrane between the cricothyroid muscles,
were dissected at the time of mobilization of the thyroid
pyramidal lobe and isthmus. The remaining level VI lymph
nodes in the paratracheal and pretracheal spaces were dissect-
ed following thyroid gland removal. Medial and lateral dis-
section margins were defined using diathermy and surgical
clips. The fibrofatty tissue in themidline was incised to expose
the trachea down to the level of the brachiocephalic vessels
inferiorly, and the medial border of the carotid artery was
dissected down to the prevertebral fascia. The superior limit
of dissection was at the level of the cricoid cartilage. The
envelope of tissue containing the unilateral level VI lymph
nodes was retracted medially and excised en bloc, using a
combination of diathermy and surgical clips to free it from the
prevertebral fascia, oesophagus and trachea. The thymus was
transected at the level of the brachiocephalic vessels and the
specimen was removed [17]. As soon as the ipsilateral level
VI dissection was finished, the contralateral central neck
dissection (CND) was undertaken to complete bilateral central
neck clearance. In each patient, the RLNs were exposed and
the branches of the superior and inferior thyroid arteries were
divided close to the thyroid capsule (peripheral ligation).
Intraoperative electrophysiological nerve integrity monitoring
was used in selected patients treated in 2004–2007. The
parathyroid glands were meticulously dissected from the thy-
roid gland and an effort was made to identify all four parathy-
roid glands and preserve as many as possible “in situ”. Any
inadvertently removed parathyroid gland found on inspection
to be lying on the thyroid capsule or within the level VI
compartment, any gland that was anatomically impossible to
be preserved, as well as any devascularized gland were elec-
tively reimplanted into the sternocleidomastoid muscle.
Postoperative follow-up
All the clinical data and pathological reports were reviewed,
and the TNM stage was assessed in each patient (based on the
seventh edition of the AJCC staging system) [18].
Radioactive I-131 ablation (RAI) was given following
thyroxine withdrawal to selected patients with thyroid
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tumours larger than 10 mm in diameter, when there were
positive lymph nodes on pathology and/or tumour extension
beyond the thyroid capsule and/or multifocal thyroid cancer.
All the patients in this study received postoperative sup-
pressive levothyroxine treatment and thyroxine doses were
adjusted to risk (to keep thyroid-stimulating hormone (TSH)
below 0.1 mU/L for high-risk patients and from 0.1 to 0.3 mU/L
for low-risk patients). A routine periodic clinical examination
(every 3 months in the initial year and then at yearly intervals)
was mandatory, including neck ultrasound, whole body scans
and serum TSH (reference range, 0.4–4.2 mU/L) and basal
thyroglobulin (Tg) levels with measurement of Tg antibodies.
For detection of serum Tg levels, between 1998 and 1999, the
DYNOtest (BRAHMS Diagnostica GmbH, Berlin, Germany)
was used with a functional sensitivity of 1.0 ng/mL, and the
Immulite 2000 assay (Diagnostics Products Corporation, Los
Angeles, CA, USA) was employed from the year 2000 onward
with a functional sensitivity of 0.2 ng/mL. Basal serumTg levels
above 2 ng/mL following TTwith or without CND in a patient
on levothyroxine suppressive therapywere classified as elevated
values (denoting a high risk of recurrent disease).
The following criteria were used to define nodal recur-
rence: either pathological evidence of disease on excision or
cytology or recurrent disease confirmed by two surveillance
modalities (e.g. elevated Tg and whole-body scan). When
possible, nodal recurrence was managed with surgical exci-
sion and repeat RAI therapy. The site of nodal recurrence and
the type of neck dissection (central level VI or lateral levels II
to V, unilateral or bilateral) performed during revision surgery
were reviewed and collected.
Indirect laryngoscopy was performed before surgery and
on the first day after operation. RLN paresis was calculated for
nerves at risk (there were 1,520 RLNs at risk in this study). In
patients with RLN paresis, additional examinations were
scheduled until vocal cord function recovered. Vocal cord
paresis for more than 12 months after the operation was
regarded as permanent.
The total serum calcium level (reference range
2.05–2.55 mmol/l) was measured 24 h after surgery and
medical treatment was initiated if the concentration was below
2 mmol/l. Medication was started on a prophylactic basis and
no patient was allowed to develop symptoms of hypocalce-
mia. Calcium salts (1.5–3.0 g Ca2+ daily) were administered
when the total serum calcium level was in the range
1.8–2.0 mmol/l and calcium plus calcitriol (0.25–1.0 μg/day)
when it was below 1.8 mmol/l. Serum calcium, serum phos-
phate and intact parathyroid hormone (iPTH; chemilumines-
cence assay, normal range 10–65 ng/l, detection limit 4.4 ng/l)
levels were determined at 4 weeks after thyroidectomy.
Hypocalcemia was defined as a total serum calcium level
below 2.0 mmol/l, irrespectively of the iPTH level. A serum
calcium level below 2.0 mmol/l with a subnormal serum iPTH
level (below 10 ng/l) was defined as transient
hypoparathyroidism if restored to normal value within
12 months following withdrawal of oral calcium or calcium
plus calcitriol therapy. Persistent hypocalcemia with the serum
iPTH level below 10 ng/l for more than 12 months after
surgery, requiring substitution with calcium with or without
calcitriol, was regarded as permanent hypoparathyroidism.
Statistical analysis
Data are presented as mean with 95 % confidence interval
(CI), unless stated otherwise. The statistical significance of
categorical variables was evaluated by the χ2 test, whereas the
Student's t test was used for the analysis of continuous vari-
ables. Odds ratios (ORs) with 95 % CI were calculated for
categorical variables. Univariable and multivariable logistic
regression analyses were performed to identify predictors of
the risk of nodal recurrence during the 5-year follow-up.
Variables considered for the univariable analysis were gender,
age, body mass index, smoking, tumour size, tumour locali-
zation in the upper third of the lobe, multifocal disease,
extrathyroid extension, positive level VI lymph nodes, the
number of level VI lymph nodes, positive/negative lymph
node ratio, metachronous distant metastasis and RAI treat-
ment. Variables achieving statistical significance at 0.1 level in
the univariable analysis were included in the multivariable
analysis. A backward variable selection procedure with the
cutoff at p <0.05 was used to identify independent predictors
of nodal recurrence during the 5-year follow-up. All the data
were prospectively collected and stored in our computer-
based institutional register of thyroid surgery and finally
retrospectively analysed by a statistician. Statistical analy-
ses were performed with Statistica® 10 for Windows®
(StatSoft, Krakow, Poland).
Results
Of 9,327 patients referred for thyroid surgery during the
study period, 987 (10.6 %) had PTC and were potential
candidates for the study. Two hundred twenty-seven pa-
tients did not meet the inclusion criteria (147 patients had
incidental diagnosis of PTC, 51 patients underwent thera-
peutic CND, 4 patients had poorly differentiated thyroid
cancer, 4 patients had distant metastasis at diagnosis) and
21 had incomplete histopathology or follow-up data, leav-
ing 760 patients who were finally included in this study
(Fig. 1). There were 624 women and 136 men with a mean
age of 53.1 years at diagnosis (95 % CI, 51.88–54.32). All
the patients in this study underwent TTwith bilateral pCND
(n =760) for staging of PTC. The mean number of lymph
nodes in a surgical specimen following TTwith pCND was
6.8 (median 7, range 4–21). Clinical and pathologic
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characteristics of patients analysed in this study are pre-
sented in Table 1.
RAI therapy was used in 618 of 760 (81.3 %) patients in
this study. All 258 (33.9 %) patients with positive lymph
nodes following pCND received RAI. The mean cumulative
dose of I-131 was 152.4 mCi (95 % CI, 135.68–169.12).
The mean follow-up of the patients was 61.7 months
(median 60, range 60–68) and 33 (4.3 %) patients were lost
to follow-up, whereas 7 (0.9 %) patients died during the study
period.
Primary outcomes
Of 760 patients with PTC included in this study, 44 (6.0 %)
developed nodal recurrence in the lateral neck during the
5-year postoperative follow-up.
Overall, 48 patients (6.3 %) developed nodal recurrence
(n =3 within level VI, n =41 within levels II to IV, n =3 within
levels II to VI, n =31 ipsilateral, n =15 contralateral and n =2
bilateral). Recurrences from skip metastases were identified in
10 (2.0 %) of 502 patients with negative level VI nodes
following pCND, while the remaining 34 (13.2 %) cases of
nodal recurrence in the lateral neck were diagnosed in 258
patients with positive level VI nodes following CND
(p <0.001). All the patients who recurred were treated with
surgery, which was followed by RAI therapy.
Nodal recurrence occurred among 8 (5.6%) of 142 patients
who did not receive RAI therapy versus 40 of 618 (6.5 %)
patients who received RAI therapy (p =0.711).
In the univariable analysis, male gender, tumour localiza-
tion in the upper third of the lobe, multifocal disease, tumour
extension through the thyroid capsule, positive level VI lymph
nodes, number of level VI lymph nodes <6 in the specimen
and positive to negative lymph node ratio ≥0.3 predicted the
nodal recurrence in the lateral neck (Table 2). In the multivar-
iable analysis, positive/negative lymph node ratio ≥0.3
(OR 14.50, 95%CI 7.21 to 29.13; p <0.001) and central lymph
node metastases (OR 7.47, 95 % CI 3.63 to 15.38; p <0.001)
were identified to be associated with an increased risk of nodal
recurrence in the lateral neck.
Secondary outcomes
Basal serum thyroglobulin level below 2 ng/mL was observed
in 718 (94.5 %) patients, while mean basal serum thyroglob-
ulin level was 0.4 ng/mL (95 % CI, 0.10–0.70) after TT with
pCND during the 5-year follow-up. SerumTg antibodies were
detected in 81 (10.7 %) patients after TT without pCND.
Transient hypoparathyroidism was observed in 243
(32.0 %) patients, while permanent hypoparathyroidism at
1 year after surgery was diagnosed in 17 (2.2 %) patients.
Parathyroid reimplantation was undertaken in 359 (47.2 %)
Fig. 1 Flow diagram of the
study. pCND prophylactic central
neck dissection, NRLN nodal
recurrence in the lateral neck
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patients. Inadvertent removal of parathyroid tissue was con-
firmed in 55 (7.2 %) of pathological reports. Unilateral tem-
porary RLN injury was identified in 50 (3.3 %) of 1,520
nerves at risk, while permanent RLN palsy at 12 months after
surgery was diagnosed in 21 (1.4 %) of 1,520 nerves at risk.
Data are shown in Table 3.
All 44 patients with nodal recurrence in the lateral neck
who underwent modified lateral neck dissection (clearance of
levels II–V) had no permanent morbidity related to this pro-
cedure (one wound infection and one chyle leak treated
conservatively).
Discussion
An area of ongoing controversy in the management of patients
with PTC is the role of pCND [20]. The rationale for
performing pCND on a routine basis includes reduced rates
of central neck recurrence, reduced morbidity with secondary
central neck lymphadenectomy, improved rates of postopera-
tive athyroglobulinemia, improved staging of the disease and
improved stratification of RAI dosage [2, 20–24]. Nevertheless,
these potential benefits are considered to be rather soft due to a
paucity of the randomized controlled trials in this field indicat-
ing improvement in hard endpoints, such as disease-specific
survival. The American Thyroid Association (ATA) estimated
that a randomized trial to evaluate pCND in PTCwould require
5,840 patients and cost an estimatedUS$15million and hence it
is hardly feasible [13]. Two meta-analyses including mostly
retrospective data have shown an absence of a clinically
Table 1 Clinical and pathological characteristics of 760 patients
analysed in this study
Characteristics TTwith pCND (n =760)
Gender
Male 136 (17.9)
Female 624 (81.1)
Age at diagnosis, years
<45 312 (41.1)
≥45 448 (58.9)
pT stagea
pT1a 228 (30.0)
pT1b 167 (22.0)
pT2 270 (35.5)
pT3 79 (10.4)
pT4a 16 (2.1)
pT4b 0 (0)
Multifocal disease (yes) 289 (38.0)
Tumour in the upper third of the lobe (yes) 266 (35.0)
Extension through thyroid capsule (yes) 84 (11.1)
Metachronous distant metastasis (yes) 4 (0.5)
TNM stagea
I 452 (59.5)
II 83 (10.9)
III 221 (29.1)
IV 4 (0.5)
Values represent numbers (percent), unless indicated otherwise; χ2 test
for all values
TT total thyroidectomy, pCND prophylactic central neck dissection
a TNM stage according to AJCC 2010 classification
Table 2 Univariable analysis of variables associated with nodal recur-
rence in the lateral neck during the 5-year follow-up
Characteristics No. of
patients
Nodal recurrence in the
lateral neck during the
5-year follow-up (n =44)
Odds ratio
(95 % CI)
p
Gender
Male 136 2.27 (1.17–4.41) 0.015
Female 624 1.00
Age (years)
≥45 448 1.01 (0.54–1.87) 0.984
<45 312 1.00
Body mass index (kg/m2)
≥30 119 1.02 (0.44–2.35) 0.047
<30 641 1.00
Smoker
Yes 251 1.05 (0.55–2.00) 0.877
No 509 1.00
Tumour size
≥10 mm 593 1.33 (0.64–2.73) 0.450
<10 mm 228 1.00
Tumour in the upper third of the lobe
Yes 266 2.35 (1.27–4.34) 0.006
No 494 1.00
Multifocal disease
Yes 289 1.85 (1.01–3.41) 0.048
No 471 1.00
Extension through thyroid capsule
Yes 84 2.55 (1.21–5.37) 0.013
No 676 1.00
Positive level VI lymph nodes
Yes 258 7.47 (3.63–15.38) <0.001
No 502 1.00
Number of level VI lymph nodes
<6 52 2.88 (1.21–6.83) 0.016
≥6 708 1.00
Lymph node ratio (positive/negative)
≥0.3 58 14.50 (7.21–29.13) <0.001
<0.3 702 1.00
Metachronous distant metastasis
Yes 4 5.52 (0.56 – 54.26) 0.142
No 756 1.00
Radioactive iodine treatment
Yes 618 2.39 (0.84–6.79) 0.102
No 142 1.00
95 % CI 95 % confidence interval
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significant reduction in disease recurrence from pCND [25, 26].
Despite this, the revised ATA guidelines from 2009 recom-
mended that pCND may be performed in patients with PTC
with clinically uninvolved central neck lymph nodes, especially
for advanced primary tumours (T3 or T4) [2]. Gyorki at al., in a
critical appraisal of the available literature, demonstrated insuf-
ficient evidence to indicate that this extra procedure performed
routinely leads to improvement in clinically meaningful end-
points [20].
Nevertheless, a recently published systematic review of
imaging-guided and pCND for PTC found metastatic central
lymph nodes in nearly half of all patients. The sensitivity of
ultrasonography and computed tomography appeared to be
poor for accurate staging of lymph nodes, ranging from 50 to
70 % [27, 28]. In contrast, our institutional experience with
pCND in cN0 PTC patients is encouraging [29]. Many other
authors are also in favour of performing prophylactic neck
dissection for optimization of staging of the disease [2, 10–12,
16, 17, 19]. In our institution, patients with cN0 PTC have
beenmanaged with TTand bilateral pCND for staging of PTC
since 1998. When compared to historical controls treated in
1993–1997, who underwent total thyroidectomy alone, bilat-
eral pCND for staging of the neck in PTC, followed by
personalized adjuvant radioiodine treatment improved both
the 10-year disease-specific survival and locoregional control
without increasing the risk of permanent morbidity [29]. In
addition, it was shown that locoregional control was signifi-
cantly better for patients who had TT with pCND (94.5 vs.
87.6% at 10 years), and this was also the case among the group
that did not receive RAI therapy [29].
In the present study, nodal recurrence in the central neck
occurred only in 6 of 727 (0.8 %) patients during the 5-year
follow-up after TT with bilateral pCND, including five cases
on the right side of the neck (in the lymph nodes beyond the
RLN) and one case on the left side of the central neck. Similar
data were reported recently by Hartl et al. who analysed the
influence of pCND on the rate of retreatment in cN0 PTC
patients in the 5-year follow-up [30]. Of 246 patients who
underwent TT alone (n =91) or TT with pCND (n =155),
overall, 12 vs. 2 % needed reoperation in the central neck,
respectively (p <0.001), with no difference in the prevalence
of permanent morbidity [30]. Thus, in a long-term observa-
tion, a routine use of TTwith pCND abolished the problem of
possible reoperation in the central neck for persistent or recur-
rent nodal disease when compared to patients who underwent
TT without pCND. In our previous study, it was shown that
most locoregional recurrences occurred within level VI of the
neck (67.6 % of all relapses) within 10 years when pCNDwas
not performed, but in a minority of patients (26.7 % of all
relapses) when pCND was done at initial surgery [29].
The present retrospective study was performed in a large
cohort of patients (n =727) with cN0 PTC who completed the
5-year follow-up after TT with bilateral pCND performed in
the years 1998–2007 and aimed at identifying risk factors for
nodal recurrence in the lateral neck, which occurred in 6.0 %
of the patients. In the multivariable analysis, central lymph
node metastases together with positive to negative lymph
node ratio ≥0.3 were identified to represent the strongest
prognostic factors for PTC recurrence in the lateral neck. It
is also of interest to note that patients with fewer than six
lymph nodes in the surgical specimen had a higher rate of
nodal recurrence in the lateral neck than those who had six
lymph nodes or more in the pathology report. Thus, to appro-
priately stage the lymph nodes status in the central neck, at
least six lymph nodes should be surgically removed and
evaluated by a pathologist; otherwise, pNx status is warranted.
Recurrences from skip metastases were identified in this co-
hort in 10 (2.0 %) of 502 patients with negative level VI nodes
following pCND, while the remaining 34 (13.2 %) cases of
nodal recurrence in the lateral neck were diagnosed in 258
patients with positive level VI nodes following CND
(p <0.001). Tumour localization in the upper third of the lobe
was associated with an increased rate of nodal recurrence in
the lateral neck in the univariable analysis, but not in the
multivariable analysis. Similar data were also reported by
others [29, 31–33]. Ricarte-Filho et al. looked for independent
prognostic factors for recurrence among lymph node-positive
patients using the multivariable analysis and showed more
than three positive nodes to be associated with a shorter
recurrence-free survival [34]. By contrast, patients under the
age of 45 with fewer than three positive nodes had no recur-
rences even without the use of RAI [34].
The prevalence of central lymph node involvement in PTC
is variable in published series, ranging from 30 to 70 %
[25, 26]. Hartl et al. analysed 317 patients with PTC who
Table 3 Secondary outcomes
Characteristics TT with pCND
(n =760)
Hypoparathyroidism, no. (%)
Total 260 (34.2)
Transient (0–12 months postop.) 243 (32.0)
Permanent (above 12 months postop.) 17 (2.2)
Parathyroid reimplantation, no. (%) 359 (47.2)
Parathyroids found in pathological report, No. (%) 55 (7.2)
Unilateral RLN injury, no. (%)*
Total 72 (4.7)
Temporary (0–12 months postop.) 50 (3.3)
Permanent (above 12 months postop.) 21 (1.4)
Basal serum thyroglobulin level <2 ng/mL, no. (%) 718 (94.5)
χ2 test for all values
TT with pCND total thyroidectomy with prophylactic central neck
dissection
a Calculation for nerves at risk, not for patients (there were 1,520 nerves at
risk in this study)
242 Langenbecks Arch Surg (2014) 399:237–244
underwent both pCND and pLND [19]. In this study, pN1
stage was 42 % overall: 23 % for unilateral pCND, 39 % for
bilateral pCND and 23 % for pLND. Fifty-five percent of the
patients staged pN1 had metastatic nodes in the lateral neck
[19]. However, only few of the positive nodes in the lateral
neck turn out to be clinically relevant in long-term observa-
tion. As indicated by the results of the present study, nodal
recurrence in the lateral neck is tenfold less frequent (6.0 %)
than the prevalence of lateral neck involvement reported in the
literature (55 %). Therefore, the majority of patients with PTC
undergoing TT with pCND, but no pLND, are likely to have
occult nodal disease left behind in the lateral neck, yet recur-
rence rates are extremely low [35]. In case of recurrent nodal
disease in the lateral neck, modified lateral neck dissection of
levels II, III, IV and V can be done safely by experienced
hands without any substantial risk of permanent morbidity
[30, 31]. Thus, in our opinion, pLND is not necessary for
staging of the neck, as recurrences arising from skip metasta-
ses are extremely rare (2 %) and identification of PTC patients
at an increased risk of recurrence in the lateral neck can be
done based on staging of the central neck. In conclusion, it is
important to acknowledge that central lymph node metastases
together with positive to negative lymph node ratio ≥0.3
represent the strongest independent prognostic factors for
PTC recurrence in the lateral neck and patients meeting the
above criteria should undergo strict surveillance.
Finally, it should be underlined that the safety of pCND is
of utmost importance. At our institution, transient but not
permanent hypoparathyroidism was more common in patients
who had TTwith pCND [29, 36], as described in other series
from high-volume centres [37, 38]. However, the risk of
permanent hypocalcemia appears to be significantly greater
at lower volume centres and was reported to be as high as
16 %, which is not acceptable [38, 39]. This issue must be
taken into consideration and pCND cannot be recommended
for low-volume thyroid surgeons.
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